Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure

Completed · Phase 1

Conditions studied: Kidney Failure, Chronic, Multiple Myeloma

In brief

The purpose of this study is to determine whether a combined bone marrow and kidney transplant will be effective in treating stage II or greater multiple myeloma and associated kidney failure. This study will determine whether transplant rejection and the need for immunosuppressive drugs are decreased with this combined transplant approach.

Key facts

Study ID

NCT00062621

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

5

Starts

2003-06-01

Expected to finish

2006-12-01

Last updated by the study team

2013-02-05

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• End-stage renal disease (ESRD) due to or in association with stage II or greater multiple myeloma
• Participants in whom the development of ESRD is not due to the underlying myeloma will be included if they have evidence of active myeloma despite past treatment with standard therapies (e.g., prednisone, melphalan, high-dose radiation therapy with autologous stem cell transplantation)
• On dialysis or have a creatinine clearance greater than 20 ml/min
• HLA-matched or one of six HLA antigen-mismatched related donor

You may not qualify if…

• Compromised pulmonary, cardiac, or liver function
• Active infection

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.